Publication: Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand
Issued Date
2005-07-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-27744528397
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.36, No.4 (2005), 994-1006
Suggested Citation
Kitiporn Srisam-ang, Amornrath Podhipak, Kulaya Narksawat, Pongsatorn Supaattagorn, Mathuros Tipayamongkholgul Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.36, No.4 (2005), 994-1006. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16922
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand
Other Contributor(s)
Abstract
This survival analysis was conducted at Ubon Ratchathani Cancer Center to determine the prognostic factors for survival of patients with stage IIIA, stage IIIB, and stage IV non-small-cell lung cancer (NSCLC) patients treated at the center between 1997-2001. The study sample included 210 patients with non-small-cell lung cancer. Diagnosis and staging were defined employing the TNM system. The majority of lung cancer patients were smokers (66.7%), lived in Ubon Ratchathani Province (40.0%), male (77.6%), and agriculturalists (74.8%). Seventy-seven percent of patients died within five years, 19.5% were lost to follow-up and 2.9% were still alive in 2003. The estimated median survival time was 6.3 months (95% CI 5.4-7.3); the median survival times for stages IIIA, IIIB, and IV were 16.3, 7.0, and 4.5 months, respectively. The overall 1-, 2- and 3-year survival rates of NSCLC were 28.9, 7.9, and 3.3, respectively. The differences in survival of patients in the various 8stages of the disease were statistically significant (p<0.0001), adjusted for age and sex. Treatment with combination methods and at an early stage in the disease were associated with significant prolongation of survival. For stage IIIA, the estimated median survival times by treatment with chemotherapy was 7.0 months, radiotherapy was 16.0 months, surgery and others 16.3 months, and chemotherapy plus radiotherapy was 19.5 months. However, only chemotherapy versus surgery and others was significantly different (p=0.0307). The median survival times for stage IIIB patients treated with chemotherapy, radiotherapy, surgery and others, chemotherapy and radiotherapy, and supportive treatment were 7.0, 7.0, 9.0, 14.7, and 3.0 months, respectively. The differences between surgery and others versus supportive treatment, chemotherapy and radiotherapy versus supportive treatment were significantly different (p=0.0392, p=0.0433, respectively). For stage IV, the median survival times for patients treated with chemotherapy, radiotherapy, chemotherapy and radiotherapy, and supportive treatment were 5.0, 4.3, 6.5, and 1.0 months, respectively. The differences between chemotherapy, radiotherapy, chemotherapy and radiotherapy versus supportive treatment, all were significantly different (p=0.0020, p<0.0001, p<0.0001, respectively). The 2-year survival rates for stages IIIA, IIIB, and IV were 16.0, 4.1, and 2.2%, respectively. The results of the study show that stage IIIA has the longest survival time. They also show that appropriate treatment is a significant factor in improving the survival of lung cancer patients.